secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037968
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance
--------------------------------------------------------------------------------

- Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).
- Net loss $14.8M ($0.30/share) vs $23.8M ($0.50) prior year; operating expenses down 6%.
- Gross margin 85.6% (vs 84.1% prior year); cash $154.5M; long-term debt $35.0M.
- FY2023 revenue guidance reaffirmed at $89-94M (25-32% YoY growth); quarterly adjusted opex ~$30.5M.
- SAHARA trial met primary signs endpoint at 6 months; Cigna covers OMNI procedures (15M lives).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/0000950170-23-037968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/sght-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer